Yayınlar & Eserler

Makaleler 85
Tümü (85)
SCI-E, SSCI, AHCI (55)
SCI-E, SSCI, AHCI, ESCI (58)
ESCI (3)
Scopus (58)
TRDizin (33)
Diğer Yayınlar (1)
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 345

8. TÜRKİYE’DE CAR-T HÜCRE TEDAVİSİNE ERİŞİM

51.Ulusal Hematoloji kongresi, Türkiye, 28 Ekim - 02 Kasım 2025, (Tam Metin Bildiri)

13. Hematolojik Hastalıkların Gelişiminde COVID-19 PCR Pozitifliği ve Aşılamanın Etkisi

50. Ulusal Hematoloji Kongresi, Antalya, Türkiye, 29 Ekim 2024, cilt.1, ss.205-207, (Özet Bildiri)

23. Possible Effect of Wilms Tumor 1 Gene Mutation on Tacrolimus Metabolism in Acute Myeloid Leukemia: Case Report

14th International Symposium on Pharmaceutical Sciences (ISOPS), Ankara, Türkiye, 25 - 28 Haziran 2024, ss.373, (Özet Bildiri)

30. PRİMER İMMÜN YETMEZLİK VE MALİGNİTE

9.KLİNİK İMMÜNOLOJİ KONGRESİ, Antalya, Türkiye, 01 Mayıs 2023, (Tam Metin Bildiri)

32. The 49th Annual Meeting of the European Society for Blood andMarrow Transplantation: Reviewers

The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Reviewers, 23 Nisan 2023, (Özet Bildiri)

35. Endotel İlişkili Transplant Komplikasyonları Ve Yönetimi

17.Ulusal Aferez Kongresi, 21 Ekim 2022, (Tam Metin Bildiri)

36. Ölçme Değerlendirme Çalışma Grubu (ÖDÇG) Sunumu

Hematoloji (Kanbilimi)’de Akreditasyon Çalışmaları Bilgilendirme Toplantısı Neredeydik, Nerelere Geldik?, 22 Eylül 2022, (Tam Metin Bildiri)

37. Strategies to improve hypomethylating-based therapy

9th Aegean Hematology Oncology Symposium, 16 - 18 Eylül 2022, (Tam Metin Bildiri)

38. DBBHL’Lİ Olguda Nadir Ekstranodal Tutulumlar

34.Ulusal Nükleer Tıp Kongresi, 27 Mart 2022, cilt.8, ss.157-158, (Özet Bildiri)

39. Prophylactic defibrotide is effective for acute graft versus host disease as well as sinusoidal obstructive syndrome

48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), Amerika Birleşik Devletleri, 19 - 22 Mart 2022, (Tam Metin Bildiri)

40. MORFOLOJİK LÖSEMİSİZ DURUMDA MLD (MORPHOLOGİC LEUKEMİA FREE STATE =MLFS) ALLOJENEİK HEMATOPOİETİK KÖK HÜCRE NAKLİ

14. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Türkiye, 10 - 12 Mart 2022, sa.177, ss.143-144, (Tam Metin Bildiri)

41. ALLOJENİK KÖK HÜCRE NAKLİ YAPILAN AML VE MDS TANILI HASTALARDA SKORLAMALARIN SAĞKALIMA ETKİSİ

14. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Türkiye, 10 - 12 Mart 2022, sa.178, ss.145-146, (Tam Metin Bildiri)

43. ERİŞKİN HASTALARDA TREOSULFAN BAZLI HAZIRLIK REJİMİ İLE ALLOJENİK KÖK HÜCRE NAKİL DENEYİMİ

14. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Türkiye, 10 Mart 2022, ss.143, (Tam Metin Bildiri)

44. “Donör seçimi: Tam Uyumlu Nakilden Haplo Nakile HLA Uyumunun Değerlendirmesi”

14.Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 10 Mart 2022, (Tam Metin Bildiri)

45. İKİNCİ ALLOJENEİK KÖK HÜCRE NAKLİ: GERÇEK YAŞAM VERİSİ

14. Ulusal kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 10 Mart 2022, (Tam Metin Bildiri)

50. HODGKİN LENFOMA TANILI HASTALARDA EKSTRANODAL TUTULUM VE YENİ TEDAVİLER

47. Ulusal Hematoloji Kongresi , Antalya, Türkiye, 4 - 07 Kasım 2021, ss.346-347, (Tam Metin Bildiri)

56. PHENOTYPES OF BONE MARROW MONOCYTES IN STEM CELL TRANSPLANTATION FOR ACUTE LEUKEMIA: A DESCRIPTIVE PILOT STUDY

8th International Congress on Leukemia Lymphoma Myeloma, İstanbul, Türkiye, 21 - 22 Mayıs 2021, sa.63, ss.48, (Tam Metin Bildiri)

58. RELAPS/ REFRAKTER HODGKİN LENFOMA HASTALARINDA ALLOJENİK HEMATOPOETİK KÖK HÜCRE NAKLİ: TEK MERKEZ DENEYİMİ

13. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Türkiye, 2 - 03 Nisan 2021, sa.52, ss.104-105, (Tam Metin Bildiri)

59. GRAFT VERSUS HOST HASTALIĞI SEBEBİ İLE RUXOLİTİNİB KULLANAN HASTALARDA ENFEKSİYON SIKLIĞININ BELİRLENMESİ

13. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Türkiye, 2 - 03 Nisan 2021, sa.137, ss.133-134, (Tam Metin Bildiri)

60. ALLOJENİK KÖK HÜCRE NAKLİ OLAN HASTALARDA CMV VİREMİSİ SIKLIĞI VE CMV VİRÜS ENFEKSİYONU İÇİN RİSK FAKTÖRLERİ- TEK MERKEZ DENEYİMİ

13. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Türkiye, 2 - 03 Nisan 2021, sa.67, ss.108-109, (Tam Metin Bildiri)

61. FLT-3 POZİTİF RELAPS REFRAKTER AML’DE POSTTRANSPLANT DÖNEMDE GİLTERİTİNİB DENEYİMİ: İKİ VAKA

13. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Türkiye, 2 - 03 Nisan 2021, sa.66, ss.151, (Tam Metin Bildiri)

62. MELFALAN JENERİKLERİ ARASINDAKİ TİFİLİT YAN ETKİ SIKLIĞININ KARŞILAŞTIRILMASI

13. Ulusal kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 02 Nisan 2021, (Tam Metin Bildiri)

66. THE IMPACT OF PRETRANSPLANT IMMUNOMODULATORY DRUGS ON CMV REACTIVATION

8 45 th International Congress on Leukemia Lymphoma Myeloma, Ankara, Türkiye, 21 Mayıs 2021, cilt.38, sa.71, ss.1-81, (Tam Metin Bildiri)

69. The impact of pretransplant ımmunomodulatory drugs on cmv reactıvatıon

8th International congress on leukemia lymphoma myeloma, 2021, 21 Mayıs 2021, (Tam Metin Bildiri)

72. GRAFT VS HOST HASTALIĞINDA ALFA- 1 ANTİTRİPSİN DENEYİMİMİZ

46. Ulusal Hematoloji Kongresi , Antalya, Türkiye, 28 - 31 Ekim 2020, sa.283, ss.117-118, (Tam Metin Bildiri)

76. MULTİPLE MYELOM’DA OTOLOG KÖK HÜCRE NAKLİ HAZIRLAMA REJİMİ OLARAK YÜKSEK DOZ MELFALAN’A BUSULFAN EKLENMESİNİN SONUÇLARI-TEK MERKEZ DENEYİMİ

13. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Türkiye, 2 - 03 Nisan 2021, sa.111, ss.126-127, (Tam Metin Bildiri)

77. CD34+ Cell Subsets in Stem Cell Products and Their Relationship with Engraftment Kinetics

46th Annual Meeting of the European Society for Blood and Marrow Transplantation, 29 Ağustos 2020, (Tam Metin Bildiri)

80. AML TANISI İLE AKRABA DIŞI VERİCİDEN AHKHN YAPILAN HASTALARDA ATG KULLANIMININ NAKİL SONUÇLARINA ETKİSİ

12. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Türkiye, 5 - 07 Mart 2020, (Tam Metin Bildiri)

83. Ibrutinib As a Promising Treatment for Pulmonary Complications Due to Refractory Chronic Graft Versus Host Disease

Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR, Florida, Amerika Birleşik Devletleri, 19 - 23 Şubat 2020, cilt.26, (Özet Bildiri) identifier

91. Can the drugs used before autologous hematopoietic stem cell transplantation have impact on CMV reactivation that results in decreased os in myeloma patients after ASCT?

45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Frankfurt, Almanya, 24 - 27 Mart 2019, cilt.54, ss.505-506, (Özet Bildiri) identifier

92. Blood group incompatibility in haplo-identical stem cell transplantation: Favor or unfavorable effect on the erythrocyte recovery?

45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Frankfurt, Almanya, 24 - 27 Mart 2019, cilt.54, ss.368-369, (Özet Bildiri) identifier

93. Haploidentical stem cell transplantation may be an option for hematological malignancies in urgent conditions

45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Frankfurt, Almanya, 24 - 27 Mart 2019, cilt.54, ss.382, (Özet Bildiri) identifier

94. Is mobilization with chemotherapy effect response in the multiple myeloma?

45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Frankfurt, Almanya, 24 - 27 Mart 2019, cilt.54, ss.500, (Özet Bildiri) identifier

96. SUCCESSFUL TREATMENT OF GRAFT FAILURE WITH SECOND ALLOGENEIC STEM CELL TRANSPLANTATION WITHOUT CONDITIONING REGIMEN

8th International Congress on Leukemia Lymphoma Myeloma, İstanbul, Türkiye, 2 - 04 Mayıs 2019, ss.75, (Tam Metin Bildiri)

98. WHAT IS THE BEST TREATMENT OPTION IN A LYMPHOMA PATIENT WITH CARDIAC THROMBUS: THROMBOLYTIC THERAPY OR SURGERY?

7th International Congress on Leukemia Lymphoma Myeloma, İstanbul, Türkiye, 2 - 04 Mayıs 2019, sa.114, ss.78, (Tam Metin Bildiri)

102. CAN AUTOLOGOUS STEM CELL TRANSPLANTATION ABROGATE THE POOR PROGNOSIS ASSOCIATED WITH HIGH LDH?

7th International Congress on Leukemia Lymphoma Myeloma, İstanbul, Türkiye, 2 - 04 Mayıs 2019, ss.45, (Tam Metin Bildiri)

103. Pretransplant hemoglobin and serum creatinine levels correlate with progression free survival in myeloma patients undergoing autologous stem cell transplantation.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2019, cilt.37, (Özet Bildiri) identifier

104. Can autologous stem cell transplantation abrogate the poor prognosis associated with high LDH in myeloma patients?

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2019, cilt.37, (Özet Bildiri) identifier

109. CAN ELTROMBOPAG TREAT THE THROMBCYTOPENIA AFTER STEM CELL TRANSPLANTATION

7th International Congress on Leukemia Lymphoma, İstanbul, Türkiye, 2 - 04 Mayıs 2019, (Tam Metin Bildiri)

112. MULTİPLE MYELOM HASTALARINDA OTOLOG PERİFERİK KÖK HÜCRE NAKLİ ESNASINDA GELİŞEN NÖTROPENİK ATEŞ

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Türkiye, 1 - 02 Mart 2019, sa.142, ss.130, (Tam Metin Bildiri)

113. OTOLOG KÖK HÜCRE NAKLİNE YANITSIZ DİFFÜZ BÜYÜK B HÜCRELİ LENFOMA’LI BİR OLGUDA BAŞARILI VENETOKLAX DENEYİMİ

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 1 - 02 Mart 2019, sa.70, ss.107-108, (Tam Metin Bildiri)

116. PRİMER İMMUN YETMEZLİKLİ ERİŞKİN HASTALARDA ALLOJENEİK NAKİL DENEYİMİ

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Türkiye, 01 Mart 2019, (Özet Bildiri)

117. İmmun Trombositopeni (İTP) hastalarında ABO kan gruplarının birinci basamak tedavi yanıtına etkisi

TKBD Uluslararası Katılımlı Hematolojik Hastalıkların Tanı Ve İzleminde Laboratuvar Sempozyumu, Türkiye, 5 - 07 Nisan 2018, cilt.16, ss.44, (Özet Bildiri)

118. Trombosit indekslerinin İmmun Trombositopeni (İTP) hastaları ve normal populasyonda karşılaştırılması

TKBD Uluslararası Katılımlı Hematolojik Hastalıkların Tanı Ve İzleminde Laboratuvar Sempozyumu, Türkiye, 5 - 07 Nisan 2018, cilt.16, ss.45, (Özet Bildiri)

120. Impact of ABO Mismatch on Outcomes of Allogeneic Hematopoietic Stem Cell Recipients: 30 Years of Experience with 1016 Patients

60th Annual Meeting of the American-Society-of-Hematology (ASH), California, Amerika Birleşik Devletleri, 1 - 04 Aralık 2018, cilt.132, (Özet Bildiri) identifier identifier

121. Is the End Close for the Graft-Versus-Host Disease That Is a Big Problem Following Allogeneic Hematopoetic Stem Cell Transplantation?

60th Annual Meeting of the American-Society-of-Hematology (ASH), California, Amerika Birleşik Devletleri, 1 - 04 Aralık 2018, cilt.132, (Özet Bildiri) identifier

124. Donor Lymphocyte Infusions for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience

60th Annual Meeting of the American-Society-of-Hematology (ASH), California, Amerika Birleşik Devletleri, 1 - 04 Aralık 2018, cilt.132, (Özet Bildiri) identifier

128. Is post-transplant albumin a predictor of early transplant complications?

44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Lisbon, Portekiz, 18 - 21 Mart 2018, cilt.53, ss.344-345, (Özet Bildiri) identifier

130. Ruxolitinib in steroid refractory GVHD treatment: single center experience

44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Lisbon, Portekiz, 18 - 21 Mart 2018, cilt.53, ss.448-449, (Özet Bildiri) identifier

131. Impact of Hepatitis B Core Antibody Seopositivity on the Liver Function Tests after Autologous Hematopoietic Stem Cell Transplantation For Multiple Myeloma

44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Lisbon, Portekiz, 18 - 21 Mart 2018, cilt.53, ss.338, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

132. Fit Elderly Patients with aggressive lymphoma do not need dose reduction of conditioning regimen

44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Lisbon, Portekiz, 18 - 21 Mart 2018, cilt.53, ss.272-273, (Özet Bildiri) identifier

134. ALLOJENEİK KÖK HÜCRE NAKLİ SONRASI GELİŞENKARACİĞER SİNÜZOİDAL TIKANIKLIK SENDROM İNSİDANSIVE KLİNİK BULGULAR

10. ULUSAL KEMİK İLİĞİTRANSPLANTASYONU VEHÜCRESEL TEDAVİLER KONGRESİ, Antalya, Türkiye, 1 - 03 Mart 2018, (Özet Bildiri)

135. Allojeneik Hematopoetik Kök Hücre Nakli Sonrası Akut Myeloid Lösemi Nüksünün Yönetimi ve Prognozu

10. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Türkiye, 1 - 03 Mart 2018, ss.126-127, (Özet Bildiri)

137. KEMOTERAPİ İLE MOBİLİZASYON MULTİPL MİYELOMDA YANITLARI ETKİLİYOR MU?

10. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 01 Mart 2018, (Tam Metin Bildiri)

139. Age is Not an Important Factor for Autologous Peripheral Hematopoietic Stem Cell Mobilization and Collection in Patients with Multiple Myeloma

Blood and Marrow Transplantion Tandem Meetings of the Center-for-International-Blood-and-Marrow-Transplant-Research (CIBMTR) / American-Society-for-Blood-and-Marrow-Transplantation (ASBMT), Utah, Amerika Birleşik Devletleri, 21 - 25 Şubat 2018, cilt.24, (Özet Bildiri) identifier

140. Dilemma-High Response Rates Vs High Toxicity: Autologous Stem Cell Transplantation for Lymphoma

59th Annual Meeting of the American-Society-of-Hematology (ASH), Georgia, Amerika Birleşik Devletleri, 9 - 12 Aralık 2017, cilt.130, (Özet Bildiri) identifier

141. Age Is Not Important for Autologous Peripheral Hematopoietic Stem Cell Transplantation in Multiple Myeloma

59th Annual Meeting of the American-Society-of-Hematology (ASH), Georgia, Amerika Birleşik Devletleri, 9 - 12 Aralık 2017, cilt.130, (Özet Bildiri) identifier

145. Engrafmanın Erken Belirteci: Büyük Boyanmamış Hücreler

43. Ulusal Hematoloji Kongresi, Antalya, Türkiye, 1 - 04 Kasım 2017, ss.53, (Özet Bildiri)

146. The outcome of haploidentical hematopoietic cell transplantations

43rd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Marseille, Fransa, 26 - 29 Mart 2017, cilt.52, (Özet Bildiri) identifier

148. Herpes simplex virus (HSV) infection in patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT)

43rd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Marseille, Fransa, 26 - 29 Mart 2017, cilt.52, (Özet Bildiri) identifier

149. Large unstained cell percentage as a predictor of efficacious peripheral stem cell mobilization in autologous stem cell transplantation

43rd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Marseille, Fransa, 26 - 29 Mart 2017, cilt.52, (Özet Bildiri) Sürdürülebilir Kalkınma identifier identifier identifier

151. Peripheral blood stem cell mobilization and collection from elderly patients (>= 65 years) with multiple myeloma: A single center experience

43rd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Marseille, Fransa, 26 - 29 Mart 2017, cilt.52, (Özet Bildiri) identifier

153. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) in advanced age adults: is it possible to transplant safely?

43rd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Marseille, Fransa, 26 - 29 Mart 2017, cilt.52, (Özet Bildiri) identifier

161. AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MANTLE CELL LYMPHOMA: SINGLE CENTER EXPERIENCE

22nd Congress of the European-Hematology-Association, Madrid, İspanya, 22 - 25 Haziran 2017, cilt.102, ss.865, (Özet Bildiri) identifier

162. NIVOLUMAB FOR RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: EXPERIENCE IN TURKEY

22nd Congress of the European-Hematology-Association, Madrid, İspanya, 22 - 25 Haziran 2017, cilt.102, ss.84-85, (Özet Bildiri) identifier

165. Comparison of myeloablative vs reduced intensity conditioning regimens in stem cell transplantations for acute myeloid leukemia.

53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, Illinois, Amerika Birleşik Devletleri, 2 - 07 Haziran 2017, cilt.35, (Özet Bildiri) identifier

166. A single center experience with two decades of follow-up on patients with hairy cell leukemia.

53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, Illinois, Amerika Birleşik Devletleri, 2 - 07 Haziran 2017, cilt.35, (Özet Bildiri) identifier

175. Evalauting peritransplant albümin decline as a predictor os acute graft versus host disease

43rdAnnual Meeting of the European Society for Blood and Marrow Transplantation, 26 - 29 Mart 2017, (Özet Bildiri)

186. OUR APPROACH TO HAIRY CELL LEUKEMIA (HCL): 31 YEARS OF EXPERIENCE

21st Congress of the European-Hematology-Association, Copenhagen, Danimarka, 9 - 12 Haziran 2016, cilt.101, ss.442, (Özet Bildiri) identifier

189. 9 THROMBOSIS IN PAROXYSMAL NOCTURNAL HEMOGLOBULINURIA PATIENTS SINGLE CENTER EXPERIENCE

24th Biennial International Congress on Thrombosis / EMLTD Congress Location: Istanbul, 4 - 07 Mayıs 2016

191. THERAPEUTIC PLASMA EXCHANGE FOR THROMBOTIC MICROANGIOPATHY

24th Biennial International Congress on Thrombosis / EMLTD Congress, İstanbul, Türkiye, 4 - 07 Mayıs 2016, cilt.141, (Özet Bildiri) identifier

192. THROMBOSIS IN PAROXYSMAL NOCTURNAL HEMOGLOBULINURIA PATIENTS: SINGLE CENTER EXPERIENCE

24th Biennial International Congress on Thrombosis / EMLTD Congress, İstanbul, Türkiye, 4 - 07 Mayıs 2016, cilt.141, (Özet Bildiri) identifier

193. Successful treatment in primary central nervous system lymphoma.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 3 - 07 Haziran 2016, cilt.34, (Özet Bildiri) identifier

194. THERAPEUTIC THROMBOCYTAPHERESIS: HIGHER PLATELET COUNTS SHOULD MATTER

24th Biennial International Congress on Thrombosis / EMLTD Congress, İstanbul, Türkiye, 4 - 07 Mayıs 2016, cilt.141, (Özet Bildiri) identifier

195. ARE AGE AND JAK2V617F MUTATION RELATED TO THROMBOSIS IN CHRONIC MYELOPROLIFERATIVE DISEASES?

24th Biennial International Congress on Thrombosis / EMLTD Congress, İstanbul, Türkiye, 4 - 07 Mayıs 2016, cilt.141, (Özet Bildiri) identifier

196. Age as a decision factor for doing autologous stem cell transplantation in fit patients with myeloma and lymphoma.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 3 - 07 Haziran 2016, cilt.34, (Özet Bildiri) identifier

198. 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation

42nd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, 3 - 06 Nisan 2016, (Özet Bildiri)

201. Dasanitib tedavisine bağlı gelişen plevral sıvı

Ulusal Akciğer Sağlığı Kongresi 2016, Türkiye, 16 - 20 Mart 2016, (Özet Bildiri)

202. Dasatinib tedavisine bağlı gelişen sıvı.

Ulusal Akciğer Sağlığı Kongresi 2016, Türkiye, 16 - 20 Mart 2016

205. Clinical Characteristics and Frequency of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplantation

42nd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, Valencia, İspanya, 3 - 06 Nisan 2016, cilt.51, (Özet Bildiri) identifier

206. Regrafting For Primary and Secondary Graft Failure

42nd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, Valencia, İspanya, 3 - 06 Nisan 2016, cilt.51, (Özet Bildiri) identifier

207. Efficacy of High Dose Corticosteroid Premedication for the Prevention of Anti-thymocyte Globulin Related Side Effects

42nd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, Valencia, İspanya, 3 - 06 Nisan 2016, cilt.51, (Özet Bildiri) identifier

211. Is Initial CD3+T Cell Dose in Donor Lymphocyte Infusion for Relapsed Hematological Malignancies a Prognostic Determinant?

57th Annual Meeting of the American-Society-of-Hematology, Florida, Amerika Birleşik Devletleri, 5 - 08 Aralık 2015, cilt.126, (Özet Bildiri) identifier

212. Comparison of Two Different Doses of Corticosteroid Premedication for Antithymocyte Globulin in Allogeneic Hematopoietic Stem Cell Transplantation

57th Annual Meeting of the American-Society-of-Hematology, Florida, Amerika Birleşik Devletleri, 5 - 08 Aralık 2015, cilt.126, (Özet Bildiri) identifier

214. Extracorporeal Photopheresis for the Treatment of Mycosis Fungoides

57th Annual Meeting of the American-Society-of-Hematology, Florida, Amerika Birleşik Devletleri, 5 - 08 Aralık 2015, cilt.126, (Özet Bildiri) identifier

215. Positive Impact of Chronic Graft-Versus Host Disease on Survival in 928 Allogeneic Hematopoietic Stem Cell Transplant Recipients

57th Annual Meeting of the American-Society-of-Hematology, Florida, Amerika Birleşik Devletleri, 5 - 08 Aralık 2015, cilt.126, (Özet Bildiri) identifier

222. Waldenström Makroglobulinemisinde Tek Merkez Deneyimi

41. Ulusal Hematoloji Kongresi, Antalya, Türkiye, 21 - 24 Ekim 2015, ss.106-107, (Özet Bildiri)

236. ALLOGENEIC STEM-CELL TRANSPLANTATION FOR ADVANCED MYCOSIS FUNGOIDES/SEZARY SYNDROME

20th Congress of European-Hematology-Association, Vienna, Avusturya, 11 - 14 Haziran 2015, cilt.100, ss.662-663, (Özet Bildiri) identifier

237. POST TRANSPLANT ERYTHROCYTOSIS IN ELEVEN CASES

20th Congress of European-Hematology-Association, Vienna, Avusturya, 11 - 14 Haziran 2015, cilt.100, ss.616, (Özet Bildiri) identifier

238. Allogeneic stem cell transplantation results in our myelodysplastic syndrome (MDS) patients.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri) identifier

239. Azacitidine in combination with ATRA, valproic acid in elderly AML patients.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri) identifier

240. Does chronic lymphocytic leukemia occur in younger adults in Turkey?

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri) identifier

241. Endoscopic evaluation of acute intestinal GVHD after allogeneic hematopoietic cell transplantation?

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri) identifier

251. Are there any optimal cell doses for graft repopulation in the Bone Marrow-Derived Allogeneic Hematopoietic Stem Cell Transplantations?

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Türkiye, 22 - 25 Mart 2015, cilt.50, (Özet Bildiri) identifier

252. Extramedullary Relapse of Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT): A Single Center Experience

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Türkiye, 22 - 25 Mart 2015, cilt.50, (Özet Bildiri) identifier

253. Generic (Bioequivalent) Melphalan Has Similar Efficacy and Toxicity but Lower Cost in the Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Türkiye, 22 - 25 Mart 2015, cilt.50, (Özet Bildiri) identifier

254. Different Doses of Anti-Thymocyte Globulin (ATG) in the Conditioning Regimen for Allogeneic Hematopoetic Stem Cell Transplantation

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Türkiye, 22 - 25 Mart 2015, (Özet Bildiri) identifier

255. Allogeneic Stem-Cell Transplantation for advanced mycosis fungoides/Sezary syndrome: Single-center experience

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Türkiye, 22 - 25 Mart 2015, cilt.50, ss.5618-5619, (Özet Bildiri) identifier

256. Allogeneic Stem-Cell Transplantation for Hodgkin and non-Hodgkin Lymphoma: Single-center experience

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Türkiye, 22 - 25 Mart 2015, cilt.50, ss.5619, (Özet Bildiri) identifier

258. Erythrocytosis following allogeneic hematopoietic stem cell transplantation in six cases

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Türkiye, 22 - 25 Mart 2015, cilt.50, (Özet Bildiri) identifier

259. Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria: Single Centre Experience

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Türkiye, 22 - 25 Mart 2015, cilt.50, (Özet Bildiri) identifier

260. Is there an optimum CD3+T cell dose for donor lymphocyte infusion?

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Türkiye, 22 - 25 Mart 2015, cilt.50, ss.5598, (Özet Bildiri) identifier

261. Prognosis of Acute Leukemia Patients with Active Disease Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Türkiye, 22 - 25 Mart 2015, cilt.50, (Özet Bildiri) identifier

262. Impact of Pre-transplant Serum Ferritin on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Türkiye, 22 - 25 Mart 2015, cilt.50, (Özet Bildiri) identifier

264. The relapse in acute leukemia after the allogeneic hematopoetic stem cell transplantation: No approaches have been superior yet

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Türkiye, 22 - 25 Mart 2015, cilt.50, (Özet Bildiri) identifier

265. Autologous Stem Cell Transplantation in Elderly Patients ( >=60 years) with Myeloma or Lymphoma: Single Center Experience

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Türkiye, 22 - 25 Mart 2015, cilt.50, ss.5622, (Özet Bildiri) identifier

266. Is it possible to overcome the catastrophic complications of Hematopoietic Stem Cell Transplantation (HSCT) using Plasma Exchange (PE)?: A Single Center's Experience

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Türkiye, 22 - 25 Mart 2015, cilt.50, ss.5581-5582, (Özet Bildiri) identifier

267. WHICH TYPE OF THE DRESSING AT THE INSERTION SITE MAY AFFECT THE RATE OF CATHETER INFECTION: GAUZE OR TRANSPARENT SEMIPERMEABLE DRESSING?

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Türkiye, 22 - 25 Mart 2015, cilt.50, ss.5532, (Özet Bildiri) identifier

268. Haploidentical Stem Cell Transplantation (SCT) Using Flamsa Regimen As Salvage Chemotherapy

56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Kostarika, 6 - 09 Aralık 2014, cilt.124, (Özet Bildiri) identifier

271. PREDICTIVE FACTORS FOR SUCCESSFUL PERIPHERAL BLOOD STEM CELL MOBILIZATION IN PATIENTS WITH MULTIPLE MYELOMA: A SINGLE CENTER EXPERIENCE

19th Congress of the European-Hematology-Association, Milan, İtalya, 12 - 15 Haziran 2014, cilt.99, ss.655-656, (Özet Bildiri) identifier

273. Hazırlama rejimi ile ilişkili çok nadir bir komplikasyon Akut Yaygın Damar içi Pıhtılaşması

8.Ulusal Kemik İliği Transplantasyonu ve Kök Hücre Tedavileri Kongresi, Türkiye, 6 - 08 Mart 2014

274. Febril Nötropeni Anketi

Febril Nötropeni Sempozyumu, Türkiye, 19 - 21 Mayıs 2013

275. A novel conditoning regimen for primary CNS lymphoma: high dose rituximab, cyclophosphamide, etoposide and BCNU (RCVB)

39th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation (EBMT), London, Kanada, 7 - 10 Nisan 2013, cilt.48, (Özet Bildiri) identifier

276. Chronicles of a brand new private stem cell transplantation unit in Turkey: nine months' experience (EBMT CIC 862)

39th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation (EBMT), London, Kanada, 7 - 10 Nisan 2013, cilt.48, (Özet Bildiri) identifier

291. Hematolojik kanserli hastalarda bakteriyemi etkenleri ve kinolon direnci

15. Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Kongresi, Türkiye, 1 - 03 Eylül 2011

296. Otolog ve Allojeneik Kök Hücre Nakli Tek Merkez Deneyimi

6.Ulusal Kemik İliği Transplantasyonu ve Kök Hücre Tedavileri Kongresi, Türkiye, 4 - 06 Mart 2010

298. Kök Hücre Nakil Ünitesi Antibiyotik Direnç Oranları Tek Merkez Deneyimi

6.Ulusal Kemik İliği Transplantasyonu ve Kök Hücre Tedavileri Kongresi, Türkiye, 4 - 06 Mart 2010

329. Allogeneic haematopoietic cell transplantation in acute myeloblastic laeukemia: Ibni Sina experience (1989-2004)

31st Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/21st Meeting of the EBMT-Nurses-Group/4th Meeting of the EBMT-Data-Management-Group, Prague, Çek Cumhuriyeti, 20 - 23 Mart 2005, cilt.35, (Özet Bildiri) identifier

330. Shall we use prophylaxis against Mycobacterium tuberculosis in tuberculin skin test positive haematopoietic cell transplant recipients?

31st Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/21st Meeting of the EBMT-Nurses-Group/4th Meeting of the EBMT-Data-Management-Group, Prague, Çek Cumhuriyeti, 20 - 23 Mart 2005, cilt.35, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

331. Peritransplant use of ultraviolet-B (UVB) phototherapy is detrimental to outcome of allogeneic stem cell transplantation.

46th Annual Meeting of the American-Society-of-Hematology, California, Amerika Birleşik Devletleri, 4 - 07 Aralık 2004, cilt.104, (Özet Bildiri) identifier

333. High-dose therapy is given to multiple myeloma patients with similar clinical characteristics to those in conventional chemotherapy and improves survival in multiple myeloma: a retrospective analysis from a single centre

30th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/20th Meeting of the EBMT-Nurses-Group/3rd Meeting of the EBMT-Data-Management-Group, Barcelona, İspanya, 28 - 31 Mart 2004, cilt.33, (Özet Bildiri) identifier

340. Kinetics of chimerism in sex-mismatched allogeneic hematopoietic cell transplantation with reduced-intensity conditioning

29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT Nurses Group/2nd Meeting of the EBMT Data Management Group, İstanbul, Türkiye, 23 - 26 Mart 2003, cilt.31, (Özet Bildiri) identifier
Kitaplar 10

2. Prolenfositik Lösemi

Hematolojik Hastalarda Patofizyoloji, Gökhan Pektaş, Editör, Holistence Publications, Çanakkale, ss.475-476, 2025 Creative Commons License

3. Basic Principles and Problems in Donor Lymphocyte Collection

Problem Solving in Apheresis Medicine, , Editör, spiringer, Adana, ss.115-133, 2025

4. Prolenfositik Lösemi

Hematolojik Hastalıklarda Patofizyoloji, PEKTAŞ GÖKHAN, Editör, Holistence Publications, Çanakkale, ss.475-476, 2025

5. Transplantasyon ile İlişkili Mikroanjiyopatik Hemolitik Anemi/Trombotik Mikroanjiyopati

Mikroanjiyopatik Hemolitik Anemiler, MEHMET SÖNMEZ, Editör, Türkiye Klinikleri Yayınevi, Ankara, ss.77-82, 2024 Creative Commons License

6. Basic Principles and Problems in Donor Lymphocyte Collection

Problem Solving in Apheresis Medicine, Ilknur Kozanoglu, Editör, springer, Adana, ss.115-133, 2024 Creative Commons License

7. İÇ HASTALIKLARI

Güneş Tıp Kitabevi, Ankara, 2023

9. Toxicity ofConditioning Regimens in Haploidentical SCT

Haploidentical Stem Cell Transplantation An emerging Treatment Modality, Taner Demirer, Editör, Springer, London/Berlin , New Jersey, ss.43-56, 2017
Metrikler

Yayın

451

Yayın (WoS)

143

Yayın (Scopus)

60

Atıf (WoS)

269

H-İndeks (WoS)

9

Atıf (Scopus)

277

H-İndeks (Scopus)

9

Atıf (Scholar)

94

H-İndeks (Scholar)

7

Atıf (TrDizin)

2

H-İndeks (TrDizin)

1

Atıf (Sobiad)

11

H-İndeks (Sobiad)

2

Atıf (Diğer Toplam)

2

Proje

19

Tez Danışmanlığı

13

Açık Erişim

17
BM Sürdürülebilir Kalkınma Amaçları